Print（PDF/145KB） May 13, 2025 Corporate

Notice Regarding Appointment of Executive and Other Key Personnel

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) plans to transition to a company with an Audit and Supervisory Committee, subject to approval at the 205th Annual Shareholders’ Meeting (the "Shareholders' Meeting") and announced today that in its meeting held on May 13, 2025, the Board of Directors appointed the candidates for executive and other key personnel following this transition, as detailed below.

1. Directors other than those who are Audit & Supervisory Committee Members

Name	As of June, 26	Current Position
Toru Kimura	Representative Director, President and CEO	Same as on the left
Motoyuki Sakai	Representative Director, Executive Vice President	Same as on the left
Tsutomu Nakagawa	Member, Board of Directors, Managing Executive Officer	Same as on the left
Hiroshi Niinuma	Member, Board of Directors	Same as on the left
Minoru Usui	Member, Board of Directors (Outside)	Same as on the left
Koji Fujimoto	Member, Board of Directors (Outside)	Same as on the left

• * The appointment is subjected to approval at the Shareholders’ Meeting.
• * The Representative Director and Executive Directors will be formally determined at the Board of Directors meeting to be held after the Shareholders’ Meeting.

2. Directors who are Audit & Supervisory Committee Members

Name	As of June 26	Current Position
Hisayoshi Kashima	Member, Board of Directors, Audit and Supervisory Committee Member	Audit & Supervisory Board Member
Yoshio Iteya	Member, Board of Directors, Audit and Supervisory Committee Member (Outside)	Audit & Supervisory Board Member (Outside)
Mayumi Mochizuki	Member, Board of Directors, Audit and Supervisory Committee Member (Outside)	Audit & Supervisory Board Member (Outside)
Daishiro Michimori	Member, Board of Directors, Audit and Supervisory Committee Member (Outside)	Audit & Supervisory Board Member (Outside)

• * The appointment is subjected to approval at the Shareholders’ Meeting.
• * The Audit and Supervisory Committee Members will be determined at the Audit and Supervisory Committee meeting to be held after the Shareholders’ Meeting.

3. Retiring members (those scheduled to retire at the conclusion of the Shareholders’ Meeting)

Name	Current Position
Saeko Arai	Member, Board of Directors (Outside)
Nobuhiro Endo	Member, Board of Directors (Outside)
Takashi Kutsunai	Audit & Supervisory Board Member

4. Audit and Supervisory Special Officer

Sumitomo Pharma has appointed an Audit and Supervisory Special Officer, who is independent from the direction and orders of the Company’s officers and employees responsible for business execution, to assist the Audit and Supervisory Committee in carrying out its duties.

Name	As of June 26	Current Position
Takashi Kutsunai	Audit and Supervisory Special Officer	Audit & Supervisory Board Member

• * The appointment is subjected to approval of the transition to a company with an Audit and Supervisory Committee at the Shareholders’ Meeting.